Restoring Balance: Current and Emerging Management of MGD (CME Monograph)

Overview

Activity Description and Purpose

Meibomian gland dysfunction is characterized by inflammation in the meibomian glands in the eyelids, which leads to poor tear film quality and exacerbated evaporation of the tear film from the ocular surface. Meibomian gland dysfunction is a major driver of dry eye disease, yet diagnosis is often delayed, leading to delayed treatment and undesirable patient outcomes. In this educational activity, experts will present real-world cases that review best practices in the early diagnosis of meibomian gland dysfunction, review current treatment strategies, and discuss emerging treatments for meibomian gland dysfunction. This educational activity is based on the proceedings of a live CME symposium that took place on Saturday, October 1, 2022. Since these proceedings, perfluorohexyloctane, 100%, and TP-03 have been approved by the US Food and Drug Administration for the treatment of dry eye disease and Demodex blepharitis, respectively. The desired results of this activity are to cement knowledge of the pathophysiology of meibomian gland dysfunction and to help ophthalmologists obtain practical strategies for screening, diagnosis, and effective treatment that can improve outcomes for patients.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

• Describe the pathophysiology of meibomian gland dysfunction–associated dry eye disease
• Implement best practices for diagnosing patients with meibomian gland dysfunction
• Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
• Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease

Registration Instructions

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.

Faculty Credentials

Faculty

	Eric D. Donnenfeld, MD (Chair) Clinical Professor of Ophthalmology New York University Langone Medical Center New York, New York Founding Partner Ophthalmic Consultants of Long Island and Connecticut Garden City, New York
	Kenneth A. Beckman, MD, FACS Clinical Assistant Professor of Ophthalmology Ohio State University Columbus, Ohio Director of Corneal Surgery Comprehensive Eye Care of Central Ohio Westerville, Ohio
	Alice T. Epitropoulos, MD, FACS Clinical Assistant Professor of Ophthalmology Ohio State University Ophthalmic Surgeons & Consultants of Ohio Eye Center of Columbus Director, Dry Eye Center of Excellence Columbus, Ohio
	Marguerite B. McDonald, MD, FACS Clinical Professor of Ophthalmology New York University Langone Medical Center New York, New York Clinical Professor of Ophthalmology Tulane University Health Sciences Center New Orleans, Louisiana Ophthalmic Consultants of Long Island Oceanside, New York

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Kenneth A. Beckman, MD, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Glint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc, TearLab Corporation, Visus Therapeutics, and Zeiss; is a contracted researcher for Aerie Pharmaceuticals, Inc, and Glaukos Corporation; and has individual stocks or stock options in RxSIGHT.

Eric D. Donnenfeld, MD, is a consultant for Alcon, Allegro Ophthalmics, LLC, Allergan, Avellino, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, CorneaGen, Covalent, Crystilex, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Pharmaceuticals, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen/LacriSciences LLP, LayerBio, Inc, LensGen, Mati Therapeutics, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, Nanowafer, Nova Bay Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, OcuHub LLC, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, PogoTec, PRN, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, Regener-Eyes, ReTEAR, Inc, Santen Inc, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has individual stocks or stock options in Avedro, Inc, CorneaGen, Covalent, Crystilex, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen/LacriSciences LLP, LayerBio, Inc, LensGen, Mati Pharmaceuticals, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, Nova Bay Pharmaceuticals, Inc, OcuHub LLC, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, Regener-Eyes, ReTEAR, Inc, Strathspey Crown, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

Alice T. Epitropoulos, MD, is a consultant for Abbott Medical Optics, AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Physician Recommended Nutriceuticals, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearScience, Visus Therapeutics, and Zeiss; is on the speakers bureau for Abbott Medical Optics, AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Physician Recommended Nutriceuticals, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TearScience; is a contracted researcher for Bausch & Lomb Incorporated; and holds a patent with Hilco Vision.

Marguerite B. McDonald, MD, is a consultant for Akorn, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCULUS, Inc, OCuSOFT Inc, Orca Surgical, Oyster Point Pharma, Inc, Santen Inc, Strōma Medical Corporation, and Sun Pharmaceutical Industries, Inc; and has individual stocks or stock options in Ocuphire Pharma.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Tony Realini, MD, MPH, is a consultant for iSTAR Medical*, Ivantis Inc*, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, and Sight Sciences.

* The financial relationship existed during the past 24 months but has now ended.

Accreditation

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

To view the MedEdicus privacy policy, visit http://mededicus.com/privacy-policy.php.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.

This CME activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 277.2